Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01033851 · ClinicalTrials.gov registry record · Phase 4
Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects
A Phase 4 study of Generalized Anxiety Disorder, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT01033851 is a Phase 4 study of Generalized Anxiety Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 89 participants, below the 213-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01033851, a Phase 4 study of Generalized Anxiety Disorder, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
Current therapies for Generalized Anxiety Disorder (GAD) have limited effectiveness. This study measures the efficacy of two different approaches to reducing anxiety and stress. One approach uses education, nutrition, exercise, and time management training, and another uses mindfulness meditation and yoga, which is taught as part of the Mindfulness-based stress reduction (MBSR) course, an 8-week manualized mindfulness intervention. We hypothesize that the two approaches will reduce anxiety in individuals with GAD in different ways. We will measure changes in stress hormones associated with these changes.
Conditions Studied
Interventions
- BEHAVIORAL Mindfulness Based Stress Reduction
- BEHAVIORAL Stress Management Education
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-03 |
| Est. Completion | 2013-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01033851
The ClinicalTrials.gov registry entry for NCT01033851 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (58% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Mindfulness Based Stress Reduction is the first listed.
NCT01033851 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01033851 about?
NCT01033851 is a clinical study titled "Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects". Current therapies for Generalized Anxiety Disorder (GAD) have limited effectiveness. This study measures the efficacy of two different approaches to reducing anxiety and stress. One approach uses education, nutrition, exercise, and time management training, and another uses mindfulness meditation an...
What is the current status of trial NCT01033851?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2008-03. Estimated completion is 2013-02.
What conditions does trial NCT01033851 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT01033851?
The interventions under investigation include: Mindfulness Based Stress Reduction (BEHAVIORAL), Stress Management Education (BEHAVIORAL).
Who is sponsoring clinical trial NCT01033851?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01033851 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brain Stimulation & Generalized Anxiety Study
ACTIVE NOT RECRUITING · Phase 4
-
Chamomile Therapy for Generalized Anxiety
COMPLETED · Phase 4
-
Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
COMPLETED · Phase 4
-
A Study of Risperidone Monotherapy in Bipolar Anxiety
COMPLETED · Phase 4
-
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
COMPLETED · Phase 4
-
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.